抑郁症中氯胺酮的剂量和暴露反应。 - Suppr

Suppr

超能文献

Dose- and exposure-response to ketamine in depression.

作者信息

Glue Paul, Gulati Abhishek, Le Nedelec Martin, Duffull Stephen

出版信息

Biol Psychiatry. 2011 Aug 15;70(4):e9-10; author reply e11-2. doi: 10.1016/j.biopsych.2010.11.031. Epub 2011 Apr 8.

DOI:10.1016/j.biopsych.2010.11.031

PMID:21481846

Abstract

摘要

相似文献

Dose- and exposure-response to ketamine in depression.

Biol Psychiatry. 2011 Aug 15;70(4):e9-10; author reply e11-2. doi: 10.1016/j.biopsych.2010.11.031. Epub 2011 Apr 8.

Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.

Biol Psychiatry. 2010 Jan 15;67(2):139-45. doi: 10.1016/j.biopsych.2009.08.038.

Intravenous Ketamine Relieves Pain and Depression After Traumatic Suicide Attempts: A Case Series.

J Clin Psychopharmacol. 2018 Apr;38(2):149-150. doi: 10.1097/JCP.0000000000000852.

[Ketamine in melancholic depression].

Ugeskr Laeger. 2010 Feb 8;172(6):460-1.

Effects of ketamine on major depressive disorder in a patient with posttraumatic stress disorder.

AANA J. 2013 Apr;81(2):118-9.

Intravenous ketamine infusion for a patient with treatment-resistant major depression: a 10-month follow-up.

J Clin Pharm Ther. 2018 Aug;43(4):581-583. doi: 10.1111/jcpt.12669. Epub 2018 Jan 25.

Ketamine as a Treatment for Adolescent Depression: A Case Report.

J Am Acad Child Adolesc Psychiatry. 2017 Apr;56(4):352-354. doi: 10.1016/j.jaac.2017.01.006.

Ketamine-induced affective switch in a patient with treatment-resistant depression.

Indian J Pharmacol. 2015 Jul-Aug;47(4):454-5. doi: 10.4103/0253-7613.161277.

Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.

Psychol Med. 2016 Feb;46(3):623-35. doi: 10.1017/S0033291715002159. Epub 2015 Oct 19.

Ketamine infusion as a treatment for major depressive disorder: a new role for anesthesiologists?

Middle East J Anaesthesiol. 2012 Oct;21(6):871-3.

引用本文的文献

Ketamine and neuroticism: a double-hit hypothesis of internalizing disorders.

Personal Neurosci. 2020 Mar 19;3:e2. doi: 10.1017/pen.2020.2. eCollection 2020.

Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments.

Int J Neuropsychopharmacol. 2019 Feb 1;22(2):119-135. doi: 10.1093/ijnp/pyy094.

Default mode network connectivity change corresponds to ketamine's delayed glutamatergic effects.

Eur Arch Psychiatry Clin Neurosci. 2020 Mar;270(2):207-216. doi: 10.1007/s00406-018-0942-y. Epub 2018 Oct 23.

Glutamatergic Modulators in Depression.

Harv Rev Psychiatry. 2018 Nov/Dec;26(6):307-319. doi: 10.1097/HRP.0000000000000183.

Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression.

Expert Rev Clin Pharmacol. 2017 Feb;10(2):153-166. doi: 10.1080/17512433.2017.1253472. Epub 2017 Jan 16.

Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder.

Curr Neuropharmacol. 2017;15(1):57-70. doi: 10.2174/1570159x14666160321123221.

Novel Glutamatergic Treatments for Severe Mood Disorders.

Curr Behav Neurosci Rep. 2015 Dec;2(4):198-208. doi: 10.1007/s40473-015-0050-5. Epub 2015 Oct 9.

Off-label use of transmucosal ketamine as a rapid-acting antidepressant: a retrospective chart review.

Neuropsychiatr Dis Treat. 2015 Oct 14;11:2667-73. doi: 10.2147/NDT.S88569. eCollection 2015.

Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.

Ther Adv Chronic Dis. 2015 May;6(3):97-114. doi: 10.1177/2040622315579059.

[Ketamine as anesthetic agent in electroconvulsion therapy].

Anaesthesist. 2015 May;64(5):357-64. doi: 10.1007/s00101-015-0027-5. Epub 2015 May 6.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Dose- and exposure-response to ketamine in depression.

Biol Psychiatry. 2011 Aug 15;70(4):e9-10; author reply e11-2. doi: 10.1016/j.biopsych.2010.11.031. Epub 2011 Apr 8.

Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.

Biol Psychiatry. 2010 Jan 15;67(2):139-45. doi: 10.1016/j.biopsych.2009.08.038.

Intravenous Ketamine Relieves Pain and Depression After Traumatic Suicide Attempts: A Case Series.

J Clin Psychopharmacol. 2018 Apr;38(2):149-150. doi: 10.1097/JCP.0000000000000852.

[Ketamine in melancholic depression].

Ugeskr Laeger. 2010 Feb 8;172(6):460-1.

Effects of ketamine on major depressive disorder in a patient with posttraumatic stress disorder.

AANA J. 2013 Apr;81(2):118-9.

Intravenous ketamine infusion for a patient with treatment-resistant major depression: a 10-month follow-up.

J Clin Pharm Ther. 2018 Aug;43(4):581-583. doi: 10.1111/jcpt.12669. Epub 2018 Jan 25.

Ketamine as a Treatment for Adolescent Depression: A Case Report.

J Am Acad Child Adolesc Psychiatry. 2017 Apr;56(4):352-354. doi: 10.1016/j.jaac.2017.01.006.

Ketamine-induced affective switch in a patient with treatment-resistant depression.

Indian J Pharmacol. 2015 Jul-Aug;47(4):454-5. doi: 10.4103/0253-7613.161277.

Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.

Psychol Med. 2016 Feb;46(3):623-35. doi: 10.1017/S0033291715002159. Epub 2015 Oct 19.

Ketamine infusion as a treatment for major depressive disorder: a new role for anesthesiologists?

Middle East J Anaesthesiol. 2012 Oct;21(6):871-3.

引用本文的文献

Ketamine and neuroticism: a double-hit hypothesis of internalizing disorders.

Personal Neurosci. 2020 Mar 19;3:e2. doi: 10.1017/pen.2020.2. eCollection 2020.

Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments.

Int J Neuropsychopharmacol. 2019 Feb 1;22(2):119-135. doi: 10.1093/ijnp/pyy094.

Default mode network connectivity change corresponds to ketamine's delayed glutamatergic effects.

Eur Arch Psychiatry Clin Neurosci. 2020 Mar;270(2):207-216. doi: 10.1007/s00406-018-0942-y. Epub 2018 Oct 23.

Glutamatergic Modulators in Depression.

Harv Rev Psychiatry. 2018 Nov/Dec;26(6):307-319. doi: 10.1097/HRP.0000000000000183.

Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression.

Expert Rev Clin Pharmacol. 2017 Feb;10(2):153-166. doi: 10.1080/17512433.2017.1253472. Epub 2017 Jan 16.

Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder.

Curr Neuropharmacol. 2017;15(1):57-70. doi: 10.2174/1570159x14666160321123221.

Novel Glutamatergic Treatments for Severe Mood Disorders.

Curr Behav Neurosci Rep. 2015 Dec;2(4):198-208. doi: 10.1007/s40473-015-0050-5. Epub 2015 Oct 9.

Off-label use of transmucosal ketamine as a rapid-acting antidepressant: a retrospective chart review.

Neuropsychiatr Dis Treat. 2015 Oct 14;11:2667-73. doi: 10.2147/NDT.S88569. eCollection 2015.

Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.

Ther Adv Chronic Dis. 2015 May;6(3):97-114. doi: 10.1177/2040622315579059.

[Ketamine as anesthetic agent in electroconvulsion therapy].

Anaesthesist. 2015 May;64(5):357-64. doi: 10.1007/s00101-015-0027-5. Epub 2015 May 6.